Thierry Facon
Thierry Facon
Patient-Reported Outcome Measures: A key to patient-tailored and outcome-driven care in Pulmonary Embolism survivors [0.03%]
基于患者的预后评估措施：以患者为导向的肺栓塞幸存者治疗的关键因素
Sophie N M Ter Haar,Cindy M M de Jong,Francis Couturaud et al.
Sophie N M Ter Haar et al.
Almost half of the acute pulmonary embolism (PE) survivors suffer from long-term sequelae that limit quality of life and their reintegration in society. The post-PE syndrome involves a spectrum of complications ranging from life-threatening...
POEMS Syndrome [0.03%]
POEMS综合征
Arnaud Jaccard,Virginie Pascal,Laurent Magy et al.
Arnaud Jaccard et al.
POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin changes) is a syndrome that involves a monoclonal B-cell proliferation, most often plasmacytic, and a variable number of manifestations listed or not in ...
Steven Chun-Min Shih,Alissa Visram,Hira Mian
Steven Chun-Min Shih
Multiple myeloma (MM) is an incurable cancer of older adults. Given the aging population, the prevalence of older adults with MM is expected to further increase over the next decade. Challenges in treating older adults result from the heter...
Michael Sang Hughes,Suzanne Lentzsch
Michael Sang Hughes
Primary systemic amyloidosis, or light chain (AL) amyloidosis, is a rare lymphoproliferative disorder in which aberrant light-chain immunoglobulins secreted into the bloodstream aggregate into fibrils and deposit into tissues, causing wides...
Nour Moukalled,Florent Malard,Ali Bazarbachi et al.
Nour Moukalled et al.
Minimal Residual Disease (MRD) in multiple myeloma has emerged as a significant prognostic factor, guiding treatment strategies and enhancing patient outcomes. Despite advancements in therapies such as proteasome inhibitors, immunomodulator...
Frank Bridoux,Nelson Leung,Samih H Nasr et al.
Frank Bridoux et al.
Renal disease is a frequent complication of symptomatic multiple myeloma, that increases morbidity and reduces quality of life and overall survival. It may result from various lesions, the most frequent being light chain cast nephropathy (L...
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today? [0.03%]
双特异抗体和嵌合抗原受体修饰的T细胞在治疗多发性骨髓瘤中的应用：目前进展如何？
Xiang Zhou,K Martin Kortuem,Leo Rasche et al.
Xiang Zhou et al.
Although the prognosis of patients with multiple myeloma (MM) has been significantly improved by the introduction of proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, MM is still considered an incurable disease in the...
Jas Virk,Jens Hillengass
Jas Virk
Multiple myeloma (MM) is the second most common adult hematologic malignancy, characterized by clonal proliferation of malignant plasma cells mostly in the bone marrow. The presence of destructive changes of the mineralized bone is a hallma...
Evolving Strategies in the Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma [0.03%]
适合移植的新诊断多发性骨髓瘤患者的管理策略的发展变化
Aurore Perrot
Aurore Perrot
Multiple myeloma treatment has evolved significantly with the introduction of triplet and quadruplet regimens, notably incorporating anti-CD38 antibodies. While autologous stem cell transplantation remains a cornerstone of therapy, its role...